Tenofovir alafenamide (TAF)
Sponsors
National Institute of Neurological Disorders and Stroke (NINDS), Janssen Scientific Affairs, LLC, The First Hospital of Jilin University, Janssen Sciences Ireland UC, National Institute of Allergy and Infectious Diseases (NIAID)
Conditions
Amyotrophic Lateral SclerosisChronic Hepatitis BDrug AdherenceEfficacy, SelfHBVHIVHIV InfectionHealthy
Early Phase 1
Phase 1
HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS)
CompletedNCT02437110
Start: 2019-04-01End: 2023-05-09Updated: 2024-01-09
Study to Evaluate the Relative Bioavailability of Fixed-dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) as a Whole Tablet, as a Split Tablet, and as Crushed Tablet in Healthy Adult Participants
CompletedNCT02984852
Start: 2016-12-31End: 2017-02-28Updated: 2025-02-03
A Single and Multiple Ascending Dose Study of JNJ-64457744
TerminatedNCT05423106
Start: 2022-07-04End: 2023-03-20Updated: 2025-02-03
Phase 2
A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection
CompletedNCT04129554
Start: 2019-11-06End: 2022-06-09Updated: 2025-02-04
A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus
CompletedNCT04535544
Start: 2020-09-17End: 2025-03-05Updated: 2026-07-22
A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection
CompletedNCT04585789
Start: 2021-03-11End: 2024-01-09Updated: 2025-05-21
A Study of JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection
CompletedNCT04667104
Start: 2021-02-01End: 2023-04-17Updated: 2024-07-03
Phase 3
Phase 4
A Perspective Study of the Antiviral Efficacy and Safety of Switching to TAF Treatment in CHB Adults With Suboptimal Response (SOR) and Intolerant to Entecavir
NCT04034368
Start: 2019-08-31End: 2021-06-30Target: 8Updated: 2019-07-26
Strengthening Hepatitis B Screening, Linkage to Care and Long-Term Monitoring in Phichit Province, Thailand: A Birth Bohort Approach
Not yet recruitingNCT07258251
Start: 2026-01-01End: 2028-12-31Target: 6000Updated: 2025-12-02
Unknown Phase
Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum
TerminatedNCT04518228
Start: 2021-09-01End: 2025-07-10Updated: 2026-08-26
Tenofovir Alafenamide Switch Therapy in Chronic Hepatitis B
RecruitingNCT05583006
Start: 2023-11-06End: 2028-12-30Target: 60Updated: 2025-01-09